Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey.

Patients with severe asthma perceive beneficial effects of biologics and good self-reported adherence to treatment, even when self-administered at home https://bit.ly/48vP70w.
Competing Interests: Conflict of interest: C. Crimi reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; honoraria received for lectures from AstraZeneca, GSK, Sanofi, Novartis, ResMed and F&P, outside the submitted work; and patent pending number 102023000013077 not discussed in the present study. Conflict of interest: C. Calabrese reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; honoraria received for lectures from AstraZeneca, GSK, Sanofi and Novartis, outside the submitted work; and support for attending meetings and/or travel received from AstraZeneca, GSK, Sanofi and Novartis, outside the submitted work. Conflict of interest: M. D'Amato reports support for the present manuscript from GlaxoSmithKline and Sanofi. Conflict of interest: F. Blasi reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; financial grants from AstraZeneca, Chiesi Farmaceutici S.p.A and Insmed Inc. outside the submitted work; consulting fees from Menarini and Zambon outside the submitted work; and speaker fees from AstraZeneca, Chiesi Farmaceutici S.p.A, GSK, Guidotti, Grifols, Insmed Inc., Menarini, Novartis AG, Sanofi-Genzyme, Viatris Inc., Vertex Pharmaceuticals and Zambon outside the submitted work. Conflict of interest: G.W. Canonica reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; research grants from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, GSK, Guidotti-Malesci, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach Pharma, ThermoFisher and Valeas outside the submitted work; honoraria for lectures from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, GSK, Guidotti-Malesci, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach Pharma, ThermoFisher and Valeas outside the submitted work; and advisory board fees from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, GSK, Guidotti-Malesci, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach Pharma, ThermoFisher and Valeas outside the submitted work. Conflict of interest: G. Guida reports support for the present manuscript from GlaxoSmithKline and Sanofi; and a speaker fee from AstraZeneca outside the submitted work. Conflict of interest: E. Heffler reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; a research grant from GSK outside the submitted work; fees for lectures from Sanofi, Regeneron, GSK, AstraZeneca, Novartis, Chiesi and Stallergenes-Greer outside the submitted work; and fees for advisory boards participation from Sanofi, Regeneron, GSK, AstraZeneca, Novartis, Chiesi and Stallergenes-Greer outside the submitted work. Conflict of interest: P. Paggiaro reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; grants for educational events from AstraZeneca, Chiesi Farmaceutici, GSK, Guidotti and Sanofi outside the submitted work; and grants for participation to Advisory Board from AstraZeneca, Chiesi Farmaceutici, GSK, Guidotti and Sanofi outside the submitted work. Conflict of interest: G.E. Carpagnano reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; and honoraria received for lectures from AstraZeneca, GSK, Sanofi and Chiesi, outside the submitted work.
(Copyright ©The authors 2023.)